Literature DB >> 7791837

A comparison of conservative and aggressive transfusion regimens in the perioperative management of sickle cell disease. The Preoperative Transfusion in Sickle Cell Disease Study Group.

E P Vichinsky1, C M Haberkern, L Neumayr, A N Earles, D Black, M Koshy, C Pegelow, M Abboud, K Ohene-Frempong, R V Iyer.   

Abstract

BACKGROUND: Preoperative transfusions are frequently given to prevent perioperative morbidity in patients with sickle cell anemia. There is no consensus, however, on the best regimen of transfusions for this purpose.
METHODS: We conducted a multicenter study to compare the rates of perioperative complications among patients randomly assigned to receive either an aggressive transfusion regimen designed to decrease the hemoglobin S level to less than 30 percent (group 1) or a conservative regimen designed to increase the hemoglobin level to 10 g per deciliter (group 2).
RESULTS: Patients undergoing a total of 604 operations were randomly assigned to group 1 or group 2. The severity of the disease, compliance with the protocol, and the types of operations were similar in the two groups. The preoperative hemoglobin level was 11 g per deciliter in group 1 and 10.6 g per deciliter in group 2. The preoperative value for hemoglobin S was 31 percent in group 1 and 59 percent in group 2. The most frequent operations were cholecystectomies (232), head and neck surgery (156), and orthopedic surgery (72). With the exception of transfusion-related complications, which occurred in 14 percent of the operations in group 1 and in 7 percent of those in group 2, the frequency of serious complications was similar in the two groups (31 percent in group 1 and 35 percent in group 2). The acute chest syndrome developed in 10 percent of both groups and resulted in two deaths in group 1. A history of pulmonary disease and a higher risk associated with surgery were significant predictors of the acute chest syndrome.
CONCLUSIONS: A conservative transfusion regimen was as effective as an aggressive regimen in preventing perioperative complications in patients with sickle cell anemia, and the conservative approach resulted in only half as many transfusion-associated complications.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7791837     DOI: 10.1056/NEJM199507273330402

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  81 in total

1.  Tonsillectomy and adenoidectomy for obstructive sleep apnea in sickle cell anemia.

Authors:  Raj Warrier; A Chauhan; U Athale
Journal:  Indian J Pediatr       Date:  2010-06-08       Impact factor: 1.967

2.  Laparoscopic cholecystectomy in adults with sickle cell disease.

Authors:  G Bonatsos; K Birbas; K Toutouzas; N Durakis
Journal:  Surg Endosc       Date:  2001-05-14       Impact factor: 4.584

3.  Current therapy of sickle cell disease.

Authors:  Zakari Y Aliyu; Ashaunta R Tumblin; Gregory J Kato
Journal:  Haematologica       Date:  2006-01       Impact factor: 9.941

4.  Recommendations for the transfusion of red blood cells.

Authors:  Giancarlo Liumbruno; Francesco Bennardello; Angela Lattanzio; Pierluigi Piccoli; Gina Rossetti
Journal:  Blood Transfus       Date:  2009-01       Impact factor: 3.443

5.  Sickle cell vasoocclusion and rescue in a microfluidic device.

Authors:  J M Higgins; D T Eddington; S N Bhatia; L Mahadevan
Journal:  Proc Natl Acad Sci U S A       Date:  2007-12-12       Impact factor: 11.205

6.  New treatments of sickle cell disease.

Authors:  S H Embury
Journal:  West J Med       Date:  1996-05

7.  Granulocyte colony-stimulating factor (G-CSF) administration in individuals with sickle cell disease: time for a moratorium?

Authors:  Courtney D Fitzhugh; Matthew M Hsieh; Charles D Bolan; Carla Saenz; John F Tisdale
Journal:  Cytotherapy       Date:  2009       Impact factor: 5.414

8.  Laparoscopic cholecystectomy in 427 adults with sickle cell disease: a single-center experience.

Authors:  Abdulrahman S Al-Mulhim; Abdulmohsen A Al-Mulhim
Journal:  Surg Endosc       Date:  2009-05-15       Impact factor: 4.584

9.  Genetic diminution of circulating prothrombin ameliorates multiorgan pathologies in sickle cell disease mice.

Authors:  Paritha I Arumugam; Eric S Mullins; Shiva Kumar Shanmukhappa; Brett P Monia; Anastacia Loberg; Maureen A Shaw; Tilat Rizvi; Janaka Wansapura; Jay L Degen; Punam Malik
Journal:  Blood       Date:  2015-08-18       Impact factor: 22.113

10.  Iron overload in sickle cell disease.

Authors:  Radha Raghupathy; Deepa Manwani; Jane A Little
Journal:  Adv Hematol       Date:  2010-05-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.